Harpoon Therapeutics stock (US4135961044): what Merck’s takeover means for biotech investors

Harpoon Therapeutics has been acquired by Merck, putting fresh spotlight on its T?cell engager platform and clinical pipeline. What does the completed deal mean for the former Nasdaq stock and for investors following oncology and immunotherapy plays?

Harpoon Therapeutics has moved out of the standalone small-cap biotech universe after being acquired by US pharma giant Merck, but its T?cell engager technology and oncology pipeline remain closely watched by investors tracking cancer immunotherapy and deal activity in the sector, according to a 2024 acquisition announcement by the companies.Merck press release as of 03/19/2024

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Harpoon Therapeutics
• Sector/industry: Biotechnology, oncology
• Headquarters/country: South San Francisco, United States
• Core markets: Oncology drug development, T?cell engagers
• Key revenue drivers: Research collaborations, potential milestone and royalty payments from partnered programs
• Home exchange/listing venue: Previously Nasdaq (ticker: HARP) before acquisition by Merck
• Trading currency: US dollar (historic listing)

Harpoon Therapeutics: core business model

Harpoon Therapeutics was founded as a clinical?stage biotechnology company focused on developing novel T?cell engager therapies for the treatment of cancer and other serious diseases, using proprietary protein engineering platforms aimed at redirecting immune cells to tumor targets.Harpoon annual report as of 03/14/2023

The company’s strategy centered on its TriTAC and ProTriTAC technology platforms, designed to create relatively small, modular proteins that could bind both to T?cells and to tumor antigens, with the goal of enabling potent tumor cell killing while managing safety and tolerability in patients, according to its prior SEC filings.Harpoon press release as of 11/03/2022

Unlike large integrated pharma groups that generate revenue from marketed drugs, Harpoon historically operated as a development?stage company without significant product sales, relying mainly on equity financing and collaboration payments from partners to fund its research and clinical trials, a common pattern among early?stage US biotech listings.

In January 2024, Merck announced an agreement to acquire Harpoon for approximately $680 million in equity value, reflecting strategic interest in the company’s immuno?oncology approach and pipeline assets, which would be integrated into Merck’s broader oncology franchise following deal completion.Merck press release as of 01/08/2024

Main revenue and product drivers for Harpoon Therapeutics

Before the acquisition, Harpoon’s potential long?term value proposition for investors was linked primarily to the clinical progress and partnering prospects of its lead TriTAC and ProTriTAC candidates, with several programs targeting solid tumors and hematologic malignancies at various stages of early clinical development.Harpoon corporate presentation as of 06/05/2023

The company reported collaboration revenue from agreements with larger pharmaceutical partners, while research and development expenses dominated its income statement, reflecting ongoing clinical trials and preclinical work; this resulted in net losses typical for development?stage oncology biotechs during the periods disclosed in its 2022 and 2023 financial filings.

Because Harpoon did not yet have an approved product on the market at the time of the Merck deal, investors historically focused on non?traditional drivers such as clinical data readouts, safety and efficacy signals from early?phase trials, and the signing or expansion of partnerships that could bring in upfront and milestone payments.

Merck highlighted in its acquisition announcement that it viewed Harpoon’s pipeline, including investigational T?cell engagers, as complementary to its existing oncology portfolio and immunotherapy strategy, suggesting that future revenue contributions would likely depend on successful development and regulatory approval of these assets within Merck’s broader clinical framework.Merck press release as of 03/19/2024

Why Harpoon Therapeutics matters for US investors

Although Harpoon shares ceased trading as an independent listing after the Merck transaction closed, the case remains relevant for US investors following the biotechnology sector, as it illustrates how large pharmaceutical companies use targeted acquisitions to bolster their oncology pipelines and access novel T?cell engager technologies.Reuters as of 01/08/2024

For investors with exposure to Merck on US exchanges, the integration of Harpoon’s assets adds another layer to the group’s cancer research portfolio, which already includes established immunotherapy treatments; pipeline diversification can influence long?term growth narratives, even though clinical and regulatory risks remain elevated for early?stage programs.

The Harpoon example also highlights the importance of due diligence on small?cap biotech names listed in New York, where outcomes can range from strategic takeovers at a premium to dilution, restructuring or pipeline setbacks, depending on trial results and the broader funding environment for life sciences companies.

Conclusion

Harpoon Therapeutics transitioned from a high?risk, development?stage Nasdaq biotech to a fully owned part of Merck’s oncology franchise, underscoring how innovative T?cell engager platforms can attract strategic buyers despite limited standalone revenue. For US investors, the story underlines both the opportunities and uncertainties inherent in early?stage immuno?oncology: attractive takeout premiums are possible, but they depend heavily on clinical data and partner appetite. Within Merck, Harpoon’s former pipeline now competes for capital and attention with many other assets, and its ultimate contribution will depend on whether key candidates progress successfully through trials and regulatory review in a crowded, fast?moving cancer treatment landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.